keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant therapy breast cancer

keyword
https://www.readbyqxmd.com/read/29334604/breast-conservation-therapy-versus-mastectomy-in-patients-with-t1-2n1-triple-negative-breast-cancer-pooled-analysis-of-krog-14-18-and-14-23
#1
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Purpose: The aim of this study is to compare the treatment outcomes of breast conserving surgery (BCS) plus radiotherapy (RT) vs. mastectomy for patients with pT1-2N1 triple negative breast cancer (TNBC). Methods: Using two multicenter retrospective studies on breast cancer, a pooled analysis was performed among 320 patients with pT1-2N1 TNBC. All patients who underwent BCS (n=212) received whole breast RT with or without regional nodal RT, while none who underwent mastectomy (n=108) received it...
January 8, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29333901/her2-positive-bilateral-metachronous-primary-breast-carcinoma-a-case-report
#2
Jinghao Yao, Jing Liu, Yawei Li, Yumei Li, Qiong Wu, Yan Yang
Human epidermal growth factor receptor 2 (HER2) positive is a unique molecular subtype of breast cancer (BC) characterized by high malignancy and poor prognosis. Bilateral primary breast cancer (BPBC) harboring HER2 gene amplification is available to be detected among the BC survivors due to the increasing use of anti-HER2 adjuvant therapy. However, owing to the paucity of cases reported, knowledge of treating HER2-positive BPBC patients including the clinical behavior, histopathologic characteristics, anti-HER2 therapeutic response and disease outcome are not fully understood...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29331262/can-interrogation-of-tumour-characteristics-lead-us-to-safely-omit-adjuvant-radiotherapy-in-patients-with-early-breast-cancer
#3
I S Bhattacharya, A M Kirby, J M Bliss, C E Coles
Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local relapse rates over recent decades. Although the proportional benefits of adjuvant radiotherapy are similar for different prognostic risk groups of patients, the absolute benefits depend on the risk of relapse and therefore vary considerably between prognostic groups. Radiotherapy is not without risk and for some patients at very low risk of relapse the risks of radiotherapy may outweigh the benefit, leading to potential overtreatment...
January 10, 2018: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29330625/facilitating-adherence-to-endocrine-therapy-in-breast-cancer-stability-and-predictive-power-of-treatment-expectations-in-a-2-year-prospective-study
#4
Yiqi Pan, Sarah R Heisig, Pia von Blanckenburg, Ute-Susann Albert, Peyman Hadji, Winfried Rief, Yvonne Nestoriuc
PURPOSE: To identify modifiable factors predictive of long-term adherence to adjuvant endocrine therapy (AET). METHODS: As part of a 2-year cohort study in primary care (n = 116), we investigated whether initial treatment expectations predict adherence at 24 months after controlling for demographic, medical, and psychosocial variables. Treatment expectations were measured as necessity-concern beliefs, expected side-effect severity, and expected coping with side effects...
January 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29328860/quality-of-life-from-canadian-cancer-trials-group-ma-17r-a-randomized-trial-of-extending-adjuvant-letrozole-to-10-years
#5
Julie Lemieux, Michael D Brundage, Wendy R Parulekar, Paul E Goss, James N Ingle, Kathleen I Pritchard, Paul Celano, Hyman Muss, Julie Gralow, Kathrin Strasser-Weippl, Kate Whelan, Dongsheng Tu, Timothy J Whelan
Purpose MA.17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and menopause-specific QOL (MENQOL; four symptom domains) at baseline and every 12 months up to 60 months...
January 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29328369/pitx2-dna-methylation-predicts-response-to-anthracycline-based-adjuvant-chemotherapy-in-triple-negative-breast-cancer-patients
#6
Magdalena Absmaier, Rudolf Napieralski, Tibor Schuster, Michaela Aubele, Axel Walch, Viktor Magdolen, Julia Dorn, Eva Gross, Nadia Harbeck, Aurelia Noske, Marion Kiechle, Manfred Schmitt
Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor prognosis; survival rates are likely to be lower with TNBC compared to other breast cancer subgroups. For this disease, systemic adjuvant chemotherapy regimens often yield suboptimal clinical results. To improve treatment regimens in TNBC, identification of molecular biomarkers may help to select patients for individualized adjuvant therapy. Evidence has accumulated that determination of the methylation status of the PITX2 gene provides a predictive value in various breast cancer subgroups, either treated with endocrine-based therapy or anthracycline-containing chemotherapy...
January 8, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29324303/first-line-vs-second-line-fulvestrant-for-hormone-receptor-positive-advanced-breast-cancer-a-post-hoc-analysis-of-the-confirm-study
#7
Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, Jasmine Lichfield, Miguel Martin
OBJECTIVES: The double-blind, phase III CONFIRM study (NCT00099437) evaluated fulvestrant 500 mg vs fulvestrant 250 mg in postmenopausal women with hormone receptor-positive locally advanced/metastatic breast cancer (LA/MBC). This post-hoc analysis investigated the efficacy and safety of fulvestrant given either first-line or second-line for advanced disease. MATERIALS & METHODS: Progression-free survival (PFS) and overall survival (OS) with fulvestrant 500 mg vs fulvestrant 250 mg was evaluated using unadjusted log-rank tests in patients treated in the first- (progression during or within 12 months after completing adjuvant endocrine therapy; n = 387) and second-line (following endocrine therapy for LA/MBC; n = 343) settings...
January 8, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29322827/hypofractionated-volumetric-modulated-arc-therapy-in-ductal-carcinoma-in-situ-toxicity-and-cosmetic-outcome-from-a-prospective-series
#8
Fiorenza De Rose, Antonella Fogliata, Davide Franceschini, Cristina Iftode, Rosalba Torrisi, Giovanna Masci, Andrea Sagona, Corrado Tinterri, Alberto Testori, Wolfgang Gatzemeier, Bethania Fernandes, Daoud Rahal, Luca Cozzi, Armando Santoro, Marta Scorsetti
OBJECTIVE: Hypofractionated radiotherapy in early stage breast cancer is an effective adjuvant treatment, but there is a lack of randomized data for patients with ductal carcinoma in situ (DCIS). Aim of this study is the evaluation of skin toxicity and cosmesis, and early clinical outcome of DCIS patients enrolled in an institutional phase II trial of hypofractionated breast irradiation. METHODS: One hundred thirty-seven DCIS patients were enrolled in the trial...
January 11, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29318276/association-of-screening-and-treatment-with-breast-cancer-mortality-by-molecular-subtype-in-us-women-2000-2012
#9
Sylvia K Plevritis, Diego Munoz, Allison W Kurian, Natasha K Stout, Oguzhan Alagoz, Aimee M Near, Sandra J Lee, Jeroen J van den Broek, Xuelin Huang, Clyde B Schechter, Brian L Sprague, Juhee Song, Harry J de Koning, Amy Trentham-Dietz, Nicolien T van Ravesteyn, Ronald Gangnon, Young Chandler, Yisheng Li, Cong Xu, Mehmet Ali Ergun, Hui Huang, Donald A Berry, Jeanne S Mandelblatt
Importance: Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden. Objective: To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions by molecular subtype based on estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)...
January 9, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29317033/emerging-breast-imaging-technologies-on-the-horizon
#10
Srinivasan Vedantham, Andrew Karellas
Early detection of breast cancers by mammography in conjunction with adjuvant therapy has contributed to reduction in breast cancer mortality. Mammography remains the "gold-standard" for breast cancer screening but is limited by tissue superposition. Digital breast tomosynthesis and more recently, dedicated breast computed tomography have been developed to alleviate the tissue superposition problem. However, all of these modalities rely upon x-ray attenuation contrast to provide anatomical images, and there are ongoing efforts to develop and clinically translate alternative modalities...
February 2018: Seminars in Ultrasound, CT, and MR
https://www.readbyqxmd.com/read/29316048/does-response-to-neo-adjuvant-chemotherapy-impact-breast-reconstruction
#11
Michael R Cassidy, Emily C Zabor, Michelle Stempel, Babak Mehrara, Mary L Gemignani
Neo-adjuvant chemotherapy (NAC) is administered in breast cancer treatment for downstaging of disease. Here, we determined the impact of response to NAC on breast reconstruction uptake. A prospective NAC and mastectomy database with or without reconstruction were reviewed with IRB approval. Univariable analyses were conducted using Kruskal-Wallis or Fisher's exact tests. Multivariable logistic regression was used to adjust for potential confounders. We identified 271 patients with unilateral breast cancer receiving NAC and either unilateral or bilateral mastectomy from 9/2013 to 5/2016...
January 8, 2018: Breast Journal
https://www.readbyqxmd.com/read/29311580/lsd1-activation-promotes-inducible-emt-programs-and-modulates-the-tumour-microenvironment-in-breast-cancer
#12
T Boulding, R D McCuaig, A Tan, K Hardy, F Wu, J Dunn, M Kalimutho, C R Sutton, J K Forwood, A G Bert, G J Goodall, L Malik, D Yip, J E Dahlstrom, A Zafar, K K Khanna, S Rao
Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying epigenetic control is poorly understood. Lysine-specific demethylase 1 (LSD1) is a key histone demethylase that alters the epigenetic landscape. Here we explored the role of LSD1 in global epigenetic regulation of EMT, cancer stem cells (CSCs), the tumour microenvironment, and therapeutic resistance in breast cancer. LSD1 induced pan-genomic gene expression in networks implicated in EMT and selectively elicits gene expression programs in CSCs whilst repressing non-CSC programs...
January 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29310623/trastuzumab-without-chemotherapy-in-the-adjuvant-treatment-of-breast-cancer-subgroup-results-from-a-large-observational-study
#13
Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Nicolas Schleif, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-Schwickardi
BACKGROUND: The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies. METHODS: An observational study database of patients with EBC receiving trastuzumab-containing (neo)adjuvant therapy was screened to identify those patients who did not receive cytostatic agents. RESULTS: Of 3935 patients, 232 (6%) were identified who received no chemotherapy, being characterized by older age, worse performance status, and/or less aggressive histology...
January 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29304773/breast-carcinoma-with-21-gene-recurrence-score-lower-than-18-rate-of-locoregional-recurrence-in-a-large-series-with-clinical-follow-up
#14
Gulisa Turashvili, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis, Hannah Y Wen
BACKGROUND: The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS risk groups predict the likelihood of distant recurrence and have recently been associated with an increased risk of locoregional recurrence (LRR). This study analyzed clinicopathologic features of patients with low RS and LRR. METHODS: In our institutional database, we identified 1396 consecutive female patients with lymph node negative, ER+/HER2- invasive breast carcinoma and low RS (<18) results, treated at our center from 2008 to 2013...
January 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29303360/flaxseed-lignans-enhance-the-cytotoxicity-of-chemotherapeutic-agents-against-breast-cancer-cell-lines-mda-mb-231-and-skbr3
#15
Yunyun Di, Franklyn De Silva, Edward S Krol, Jane Alcorn
Systemic cytotoxic chemotherapy remains the mainstay of metastatic breast cancer; however, prognosis and overall survival is unfavorable due to inadequate treatment response and/or unacceptable toxicity. Natural compounds and their active metabolites receive increasing attention as possible adjuvant therapy with cancer chemotherapeutics to improve treatment response, survival rates, and quality of life of breast cancer patients. This study investigated the combination of flaxseed lignans (Secoisolariciresinol and Enterolactone) with classic chemotherapeutic agents (Docetaxel, Doxorubicin, and Carboplatin) with different mechanisms of action to determine whether flaxseed lignans could enhance the cytotoxic effect of such drugs in the metastatic breast cancer cell lines, SKBR3 and MDA-MB-231...
January 5, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/29302485/21-gene-recurrence-assay-in-patients-receiving-intraoperative-radiotherapy-are-favorable-characteristics-a-surrogate-for-low-recurrence
#16
Bridget A Oppong, Surupa Sen Gupta, Monique Gary, Patricia Wehner, Mihriye Mete, Danjing Zhao, Sulakshana Seevaratnam, Sonali Rudra, Shawna C Willey
Background: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC. Methods: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013-2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy. Results: The mean age was 68 years...
December 2017: Gland Surgery
https://www.readbyqxmd.com/read/29296238/the-implication-from-ras-raf-erk-signaling-pathway-increased-activation-in-epirubicin-treated-triple-negative-breast-cancer
#17
Jianbo Huang, Qingqing Luo, Yun Xiao, Hongyuan Li, Lingquan Kong, Guosheng Ren
Background: Triple negative breast cancer (TNBC) is not sensitive to RAS/RAF/ERK signaling pathway (ERK pathway) targeting therapy, due to the absence of excessive activation of ERK pathway. However, the kinase cascades might be activated after chemotherapy in TNBC. Here we aimed to predict whether ERK pathway targeting therapy could be used as an adjuvant therapy in TNBC. Methods: Within online GEO datasets (GSE43816 and GSE54326), gene set enrichment analysis (GSEA) was performed to detect molecular changes in epirubicin treated TNBC samples and cells, ERK pathway components and regulation genes changes were included...
December 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/29291168/metronomic-chemotherapy-for-non-metastatic-triple-negative-breast-cancer-selection-is-the-key
#18
REVIEW
Connie Rabanal, Rossana Ruiz, Silvia Neciosup, Henry Gomez
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer, and is still defined as what it is not. Currently, TNBC is the only type of breast cancer for which there are no approved targeted therapies and maximum tolerated dose chemotherapy with taxanes and anthracycline-containing regimens is still the standard of care in both the neoadjuvant and adjuvant settings. In the last years, metronomic chemotherapy (MC) is being explored as an alternative to improve outcomes in TNBC. In the neoadjuvant setting, purely metronomic and hybrid approaches have been developed with the objective of increasing complete pathologic response (pCR) and prolonging disease free survival...
December 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29290564/adherence-to-adjuvant-endocrine-therapy-in-women-with-breast-cancer-a-prospective-observational-study-in-japanese-women
#19
Sayaka Kuba, Shigeto Maeda, Megumi Matsumoto, Kosho Yamanouchi, Hiroshi Yano, Michi Morita, Chika Sakimura, Toshiko Hatachi, Yukiko Tokai, Mitsuhisa Takatsuki, Hikaru Fujioka, Naomi Hayashida, Takeshi Nagayasu, Susumu Eguchi
INTRODUCTION: Nonadherence to adjuvant endocrine therapy has been poorly studied in Asian patients with breast cancer. We therefore assessed adherence to endocrine therapy among women with breast cancer in Japan. PATIENTS AND METHODS: We conducted a prospective observational study among Japanese women with hormone receptor-positive breast cancer. Patients brought their pill packets to visits for 1 year and answered a questionnaire. We also examined prescription records during the study period...
December 12, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29289334/does-preoperative-axillary-staging-lead-to-overtreatment-of-women-with-screen-detected-breast-cancer
#20
M G Wallis, F Kilburn-Toppin, S Taylor-Phillips
AIM: To determine the impact of preoperative axillary ultrasound staging in a screen-detected breast cancer population. MATERIALS AND METHODS: Ultrasound and needle biopsy staging results alongside reference standard sentinel lymph node biopsy and axillary lymph node dissection were extracted retrospectively from the unit's computer records between 1 April 2008 and 31 March 2015. Axillary staging was compared with final histopathology and treatment. RESULTS: Of the 215,661 screening examinations performed, 780 invasive cancers were diagnosed, which had preoperative axillary staging data, of which 162 (20...
December 27, 2017: Clinical Radiology
keyword
keyword
118674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"